Details for Patent: 7,939,516

Summary for Patent: 7,939,516

Title:	Topical skin care composition
Abstract:	A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.
Inventor(s):	Puglia; Nancy (Sanford, FL), Roth; Jerry (Sanford, FL), Ramirez; Rosario (Sanford, FL)
Assignee:	Galderma S.A. (Cham, CH)
Application Number:	11/747,806
Patent Claim Types: see list of patent claims	Composition; Process; Formulation;
Scope and claims summary:	Title: PolyAminoether Derivatives for RNA Interference Patent Number: US 7939516 B1 Issued Date: May 3, 2011 United States Patent 7939516, assigned to Alnylam Pharmaceuticals, Inc. and related institutions, pertains to novel polyaminoether derivatives used for RNA interference (RNAi) applications. These derivatives are designed as chemical modifications of RNA-containing molecules to enhance their stability, delivery, and efficacy in siRNA (short interfering RNA) therapies. Scope of the Patent: This patent covers a broad class of polyaminoether derivatives encompassing various types of RNA or DNA molecules conjugated with specific amino ether side chains. The disclosed compounds are designed to improve the pharmacokinetic and pharmacodynamic properties of siRNA-based therapeutics, facilitating their widespread use in treating various diseases, such as cancer, viral infections, and genetic disorders. Key Features and Claims: Structure-Function Relationship: The patented compounds possess specific chemical features that enhance their stability and interaction with both the siRNA backbone and the target mRNA. Conjugate Formulations: The polyaminoether-modified RNAi agents can be formulated as liposomes, nanoparticle formulations, or direct conjugations to target cells or tissues, including site-specific or systemic delivery methods. Synthesis Methods: The patent provides information on the synthesis of these versatile derivatives using various chemical approaches, including modification of existing RNAi agents. Therapeutic Applications: The scope of the patent includes a wide range of therapeutic indications where RNAi-based treatments can be applied, such as cancer (e.g., lung, liver, and pancreatic) and various viral diseases. Key Points: The disclosure covers modifications of siRNA and other RNA-containing molecules to enhance their in vivo delivery, stability, and efficacy. Patented structures exhibit improved polyethylene glycol (PEG) tolerance and potentially maintain higher thermostability and resistance to nucleases and serum components. Novel conjugate formulations provide increased lipophilicity to aid in stable encapsulation in liposomes or lipid nanoparticles. Research utilizing this invention might advance developments targeting difficult-to-reach tissues and enhance delivery of potentially problematic molecules. Alnylam Pharmaceuticals' relevance to this patent represents significant advancements in the field of RNA biology, pushing the boundaries of RNA based therapeutics and ultimately providing innovative targeted treatments for previously difficult to treat diseases.

Drugs Protected by US Patent 7,939,516

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,939,516

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003284353
Brazil	0314882
Brazil	PI0314882
Canada	2503539